[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,271
Citations 0
JAMA Clinical Evidence Synopsis
June 7, 2016

Treatment of Fatigue in Parkinson Disease

Author Affiliations
  • 1Department of Physiotherapy, University of Applied Sciences, Leiden, the Netherlands
  • 2Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, the Netherlands
  • 3Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
JAMA. 2016;315(21):2340-2341. doi:10.1001/jama.2016.5260
Abstract

Clinical Question  Which pharmacological and nonpharmacological interventions are associated with improvement in general, physical, or mental fatigue and minimal adverse effects in patients with Parkinson disease (PD)?

Bottom Line  Rasagiline, modafinil, and doxepin are associated with improvement in fatigue and are not associated with increased risk of adverse effects in patients with PD. However, the quality of evidence is limited and does not provide a clear basis for treatment decisions.

×